Placon Therapeutics logo

Placon Therapeutics

Placon Therapeutics is developing next-generation novel platinum medicines designed to improve the efficacy and side effect profile of today’s cytotoxic medicines that are widely used in cancer treatment. Our albumin-conjugating platinum drug candidates have long circulating half lives and preferentially accumulate in tumors, offering the potential for significantly enhanced tumor growth inhibition and reduced side effects based on preclinical studies. BTP-114 is the company’s lead program and is prepared to enter clinical studies with an approved investigational new drug application (IND) from the U.S. Food and Drug Administration (FDA). Placon will pursue clinical development for BTP-114 in collaboration with a strategic partner or other investors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50
Users (0 votes) {{ reviewsOverall }} / 50
What people say... Login to rate
Order by:

Be the first to leave a review.

Verified
{{{ review.rating_title }}}

Show more
{{ pageNumber+1 }}

KEY DETAILS

Websitehttp://www.placontx.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
MA
Boston
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/placon-corporation” connections=”true” suffix=””]